As I understand it Hemophilia A or Factor VIII deficiency is much more common than Hemophilia B or Factor IX deficiency so I find it interesting that GTCB decided not to collaborate with LFB on Factor VIII. I think they sold out on EU Factor IX to get the cash and wish to partner with an alternative plasma company for factor VIII/IX marketing to get a better deal. The market could turn out to be pretty sizable if cost efficiencies could bring the price down enough to make chronic rather than 'acute only' replacement feasible. I think that's the whole idea behind the pig project and should not be overlooked as a potentially large source of revenue. The pig people practically gave away the market to the western world due to the patent on mammal milk production held by GTCB. It all makes sense to me.
Market Data 
Markets 
AI
